Αggrafiban

Tirofiban Hydrochloride Monohydrate, sold as Aggrastiban, is an intravenous antiplatelet medication used to prevent blood clots in high-risk patients. This EU-manufactured drug helps maintain blood flow in coronary conditions. Suitable for short-term use under medical supervision.

Aggrastiban is primarily used to reduce the risk of heart attack and stroke in patients with unstable angina or those undergoing certain cardiac procedures. It works by preventing platelets from clumping together, which can block blood vessels. This medication is often prescribed for short-term use in hospital settings to support coronary health.

Aggrastiban helps maintain normal blood flow by reducing the formation of dangerous blood clots. Patients may experience improved circulation and reduced chest discomfort when used as directed. Common effects include a feeling of stability during cardiac monitoring, though individual responses vary.

Aggrastiban should only be administered by healthcare professionals in a controlled setting. Patients with a history of bleeding disorders or recent surgery may need special monitoring. Regular blood tests may be required to ensure safe use. Always disclose full medical history before administration.

Aggrastiban may interact with other blood thinners, NSAIDs, or medications affecting platelet function. Combining it with certain drugs could increase bleeding risk. Alcohol and herbal supplements like ginkgo may also pose risks. Consult a healthcare provider before mixing medications.